Benjamin Graham Detailed Fundamental Analysis

Validea's guru fundamental report rates Regeneron Pharmaceuticals (REGN) at 71% using its Benjamin Graham-inspired Value Investor model, placing it below the 80% threshold for 'some interest' by this deep value methodology. While REGN passes several fundamental criteria like sales and long-term EPS growth, it fails on key valuation metrics, specifically its P/E and Price/Book ratios, indicating it does not align with strict deep value investment principles despite operational strengths.

Analysis

Regeneron Pharmaceuticals (REGN) scores 71% on a Validea model based on Benjamin Graham's deep value strategy, a rating that falls below the 80% threshold indicating strategic interest. The analysis reveals a dichotomy between the company's operational health and its valuation. REGN exhibits strong fundamentals, passing criteria for sales, current ratio, low long-term debt relative to net current assets, and solid long-term EPS growth. However, it fails on the core valuation metrics central to the Graham methodology: the Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios are deemed too high. This suggests that while the company is fundamentally sound, its current market price does not offer the margin of safety required by a strict deep value discipline. The stock's classification as a 'large-cap growth' name aligns with this finding, as such stocks typically trade at higher multiples than what this particular value screen would find acceptable.

Key Decisions for Investors

• Deep value investors adhering to Graham's principles should approach with caution, as REGN's current P/E and P/B ratios explicitly fail this model's valuation tests, indicating it is not a classic value play at its current price.
• Investors with a growth or Growth at a Reasonable Price (GARP) mandate may find the strong fundamental signals, such as robust long-term EPS growth and a healthy balance sheet, to be a compelling reason to investigate whether the company's growth trajectory justifies its premium valuation.
• Consider monitoring REGN for a potential price correction; a significant pullback that brings its P/E and P/B ratios to more attractive levels could present a buying opportunity, especially if its underlying operational strengths remain intact.